CHRS
Coherus BioSciences Inc
1.20$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.8% | +21.3% | -11.6% | -25.2% | -11.2% | -17.3% | +18.4% | +17.5% | -50.0% | +3.0% | -28.1% | |
| – | +7.0% | +31.9% | -11.1% | -33.9% | -7.4% | -9.2% | +22.6% | +21.2% | -55.2% | -0.3% | -35.1% | |
| – | +27.5% | +152.5% | -38.7% | -38.7% | +29.0% | -34.6% | +163.2% | -52.3% | -14.0% | +29.7% | -28.0% | |
| – | -10.5% | +120.6% | -38.7% | -38.7% | +29.0% | -34.6% | +188.4% | -19.3% | -10.2% | -2.9% | -37.0% | |
| – | +20.3% | +9.1% | +10.4% | -36.6% | -38.5% | -49.0% | +91.6% | +109.4% | -92.6% | +22.2% | -36.7% | |
| – | -6.3% | -1.0% | +0.3% | -23.4% | +47.1% | -95.0% | +28.3% | -54.6% | +54.9% | +52.1% | +17.5% | |
| – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | +55.2% | -19.3% | -2.9% | -2.1% | -1.2% | -1.2% | -1.3% | -5.4% | -6.6% | -1.4% | -1.4% | |
| – | +14.7% | +2.7% | -10.2% | -21.9% | -2.1% | -4.5% | -42.4% | +34.1% | -54.0% | -5.0% | -30.4% | |
| – | +38.4% | +62.3% | -14.0% | -36.2% | -4.3% | -9.9% | +4.0% | +41.0% | -62.0% | -6.7% | -42.9% | |
| – | -52.0% | +8,142.9% | -97.7% | -60.4% | +3.8% | +1.9% | +1.9% | +2.0% | +2.1% | +3.9% | – | |
| – | -5.0% | +8.7% | +100.6% | -71.5% | +30.0% | +43.8% | -8.1% | -33.8% | -60.2% | +15.8% | +14.7% | |
| – | +0.1% | -36.7% | -11.9% | +0.2% | +0.2% | +0.2% | -86.1% | +0.2% | +0.3% | +0.3% | +0.3% | |
| – | – | – | – | – | – | – | – | -26.7% | -30.5% | +28.9% | -22.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +14.1% | +12.6% | -8.5% | +0.3% | +0.2% | +0.4% | +0.2% | +0.1% | +3.6% | +13.3% | +13.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.